Navigation Links
Cato Research Ltd. and Advanced Targeting Systems, Inc. Partner to Develop SP-SAP for Chronic Pain
Date:4/3/2008

DURHAM, N.C., and SAN DIEGO, April 3, 2008 /PRNewswire/ -- Cato Research Ltd., a global contract research and development organization, and Advanced Targeting Systems, Inc. (ATS), a privately held biotechnology company, announced today a new strategic alliance focused on development and commercialization of SP-SAP, ATS's lead drug candidate for chronic pain. Advanced Pain Therapeutics LLC (APT), a new strategic development company formed by Cato Research, ATS, and Cato BioVentures, the venture capital affiliate of Cato Research, obtained exclusive, worldwide rights to develop, manufacture, use, and sell SP-SAP for the treatment of severe chronic pain. Cato Research will provide CRO services to the new company.

SP-SAP is a single-dose, nonopioid, substance P receptor-targeted treatment designed to specifically bind to and eliminate a subset of neurons that send the chronic pain signal to the brain. Preclinical studies in animal models have shown that SP-SAP eliminates chronic pain without disrupting other sensory modalities or motor function and is well tolerated.

"When we partner early, as we have here, we can make a major difference in the overall development of promising drug candidates such as SP-SAP," said Lynda Sutton, COO of Cato Research and CEO of Advanced Pain Therapeutics. "The flexible, broad-based relationships among APT, ATS, and Cato Research position us well to execute our innovative drug development model."

Denise Higgins, Vice President of ATS, affirms that this arrangement allows for a unique synergy between the companies. "We are enthusiastic about working with APT and Cato Research to help address the under-served chronic pain population. Our preclinical work with SP-SAP makes us very optimistic about the impact this innovative treatment can have for those who are suffering."

Chronic disease states and tissue damage can lead to chronic pain. In particular, terminally ill patients often experience severe, chronic pain due to advancement of disease or unwanted side effects of treatment. Although in many cases, standard treatments, such as opioids, can control pain, there is a significant subset of patients who cannot find relief through standard care. Use of opioids can also be associated with unwanted, severe side-effects. In these cases, sedation or cordotomy may be a patient's only option for pain relief. Hence, severe chronic pain represents a serious, poorly met medical need. SP-SAP offers a novel approach to target a specific set of neurons involved in chronic pain and as such, has the potential to revolutionize the way severe chronic pain is treated.

About Advanced Pain Therapeutics

Headquartered near Research Triangle Park, privately held APT will work with Cato Research and Cato BioVentures to develop and commercialize SP-SAP as a novel, nonopioid treatment for severe chronic pain, with minimal adverse side effects.

About Cato Research

Founded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a global, full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. With a staff of more than 300 employees located in the United States, Europe, Canada, Israel, and South Africa, Cato Research's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval.

About Advanced Targeting Systems

A San Diego-based biotechnology company, ATS is a pioneer in the use of toxin conjugates targeted to eliminate specific cells through a powerful technique called Molecular Neurosurgery. Since 1994, Dr. Douglas Lappi, the leading expert in the manufacture and use of targeted toxins, and his team at ATS have been developing and selling reagents to the research community and major pharmaceutical companies. The current product line includes targeted toxins, antibodies and custom services designed to assist scientists in the study of nervous system function, brain-related diseases and disorders. The technology that provides the foundation for ATS's products has a broad spectrum of clinical applications, such as pain, cancer, autoimmune disorders and infectious diseases.


'/>"/>
SOURCE Cato Research Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Diabetes Research, Advocacy and Education Gets Big Boost with Donation of Two- Year Lease for 2008 Chrysler Sebring Convertible
2. Researchers ID gene linked to lung cancer
3. Drexel School of Public Health awarded $14M NIH grant for autism research
4. Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market
5. Alberta physiologist earns top national honor for spinal cord research
6. Families of children with cancer support human tissue research, study finds
7. USC researchers find new clues to risk of Hodgkin lymphoma
8. Researchers develop new method to test for lung cancer
9. Latest Advances in Diabetes Research to be Presented in San Francisco, California at Worlds Largest Diabetes Conference, June 6-10, 2008
10. UCLA researchers design nanomachine that kills cancer cells
11. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Omaha, NE (PRWEB) , ... February 12, 2016 , ... ... list of the five most searched jobs via the website of healthcare staffing leader ... professionals in travel nurse jobs , travel therapy positions and in ...
(Date:2/12/2016)... Texas (PRWEB) , ... February 12, 2016 , ... Yisrayl ... a revealing article this week that uncovers what he says are the real facts ... stories of the Bible from parents and Sunday school teachers, and Yisrayl says there ...
(Date:2/12/2016)... ... , ... With the exception of restorative dentistry, to date there has been no other option ... by the FDA, there is a now a new protocol in stopping cavity progression; Silver ... and quick to apply. The application is as simple as drying the tooth and ...
(Date:2/11/2016)... ORLEANS (PRWEB) , ... February 11, 2016 , ... “ ... Achieving Satisfaction through a Well Managed Mind” (published by Balboa Press) teaches readers how ... way of being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western ... (AOA) Match Program Tuesday, February 9, taking one of the final steps in ... medical education positions across the country. Of the 103 student-doctors who comprise the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... N.Y. , Feb. 11, 2016  Governor Andrew ... that will create 1,400 jobs throughout Western ... a partnership with the SUNY Polytechnic Institute, includes a ... Conventus Building in Buffalo , as ... foot manufacturing facility in Dunkirk . ...
(Date:2/11/2016)...  NOIT™ Research LLC, a private, leading-edge autism research ... to assist needy families in obtaining one of its ... February 10, 2016 and March 31, 2016, the company ... NOIT is an auditory stimulus that plays a key ... Beth Shier , NOIT Research director. ...
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
Breaking Medicine Technology: